Adoptive transfer of tumor-infiltrating lymphocytes (TILs) and genetically engineered T
lymphocytes expressing chimeric antigen receptors (CARs) or conventional alpha/beta T …

Cancer can be effectively targeted using a patient's own T cells equipped with synthetic
receptors, including chimeric antigen receptors (CARs) that redirect and reprogram these …

Adoptive cellular therapy (ACT) is an immunotherapy which involves the passive transfer of
lymphocytes into a lymphodepleted host after ex vivo stimulation and expansion. Tumor …

Highlights•Adoptive cellular therapy is represented by 3 major modalities: tumor-infiltrating
lymphocyte therapy, CAR/TCR-engineered cell therapy and endogenous T cell …

Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy
that can comprise naturally occurring ex vivo expanded cells (eg, tumor-infiltrating …

Simple Summary The aging of the world population leads to a constant increase of cancer-
related morbidity and mortality. Treatment of late-stage tumors has become a significant …

Adoptive transfer of naturally occurring or genetically engineered T cells is an effective
treatment for certain haematological malignancies, such as non-Hodgkin lymphoma and …

Accumulating clinical evidence suggests that adoptive T-cell immunotherapy could be a
promising option for control of cancer; evident examples include the graft-vs-leukemia effect …

Adoptive T cell transfer for cancer and chronic infection is an emerging field that shows
promise in recent trials. Synthetic-biology-based engineering of T lymphocytes to express …

Adoptive-cell therapy, including the transfer of tumor-infiltrating T lymphocytes after in vitro
expansion or T cells redirected to tumor antigens using antigen-specific transgenic T-cell …